CN106699812A — 替诺福韦前药的制备和纯化方法
Assigned to Jiangsu Hansoh Pharmaceutical Group Co Ltd · Expires 2017-05-24 · 9y expired
What this patent protects
本发明涉及替诺福韦前药的制备和纯化方法。具体是9‑[(R)‑2‑[[(S)‑[[[1‑(异丙氧基羰基)‑1‑甲基]乙基]氨基]苯氧基氧膦基]甲氧基]丙基]腺嘌呤的制备和纯化方法。本方法以包含两种异构体的混合物(中间体1)为起始原料，结晶去除部分杂质得到中间体2，再使用拆分剂对中间体2进行拆分得到中间体3，中间体3经过重结晶，进一步提高纯度得到中间体4，最后游离去除拆分剂得到9‑[(R)‑2‑[[(S)‑[[[1‑(异丙氧基羰基)‑1‑甲基]乙基]氨基]苯氧基氧膦基]甲氧基]丙基]腺嘌呤。本发明避免了HPLC制备柱分离纯化操作，适合工业化生产，且产率高，纯…
USPTO Abstract
本发明涉及替诺福韦前药的制备和纯化方法。具体是9‑[(R)‑2‑[[(S)‑[[[1‑(异丙氧基羰基)‑1‑甲基]乙基]氨基]苯氧基氧膦基]甲氧基]丙基]腺嘌呤的制备和纯化方法。本方法以包含两种异构体的混合物(中间体1)为起始原料，结晶去除部分杂质得到中间体2，再使用拆分剂对中间体2进行拆分得到中间体3，中间体3经过重结晶，进一步提高纯度得到中间体4，最后游离去除拆分剂得到9‑[(R)‑2‑[[(S)‑[[[1‑(异丙氧基羰基)‑1‑甲基]乙基]氨基]苯氧基氧膦基]甲氧基]丙基]腺嘌呤。本发明避免了HPLC制备柱分离纯化操作，适合工业化生产，且产率高，纯度好。
Drugs covered by this patent
- Emtriva (EMTRICITABINE) · Gilead Sciences
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.